Clinical Trial: To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure

Brief Summary:

Study population: Patients admitted or seen in OPD (Out Patient Department), Department of Hepatology.

Study design- Prospective Randomized Controlled Trial. Study period-January 2016 to May 2017 Intervention- Subjects will be randomized into 3 groups Group A subjects will receive ω3 PUFA (Polyunsaturated Fatty Acids) (10% Omegavan 100 ml).

Group B- will receive ω6 PUFA (Polyunsaturated Fatty Acids) (10% Intralipid 100 ml).

Group C -Placebo group

Monitoring and assessment- :- The following tests will be done in these patients:-

  1. Complete clinical examination.
  2. Serum electrolytes- sodium, potassium, calcium, magnesium, phosphate levels
  3. BUN (Blood Urea Nitrogen)
  4. Serum free fatty acid levels
  5. Lipid profile.
  6. Arterial ammonia
  7. Arterial lactate
  8. Blood sugar and serum insulin levels